The total return over the past 12 months is +23.41% vs. +16.94% for the S&P 500. So far it's up +29.04% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | +23.41% | +81.63% | +33.72% | N/A | N/A | N/A |
| Total Return CAGR | +23.41% | +81.63% | +33.72% | N/A | N/A | N/A |
| Revenue CAGR | +36.33% | +35.74% | +58.33% | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Xeris Biopharma Holdings, Inc. (XERS)
| Year | Start price | End price | XERS Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $7.85 | $10.13 | +29.04% | +14.51% | +14.53% |
| 2025 | $3.39 | $7.85 | +131.56% | +17.72% | +113.84% |
| 2024 | $2.35 | $3.39 | +44.26% | +24.89% | +19.37% |
| 2023 | $1.33 | $2.35 | +76.69% | +26.19% | +50.50% |
| 2022 | $2.93 | $1.33 | (54.61%) | (18.17%) | (36.44%) |
| 2021 | $4.92 | $2.93 | (40.45%) | +28.74% | (69.19%) |
| 2020 | $7.05 | $4.92 | (30.21%) | +18.37% | (48.58%) |
| 2019 | $17.00 | $7.05 | (58.53%) | +31.22% | (89.75%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
